MCKesson stock rises on earnings growth and 31.3% EPS expansion

MCKesson stock reflects a business that posted $359.9 billion in revenue for fiscal 2025 and adjusted EPS growth of 31.3%, while the latest quoted market value remains tied to the company’s large-scale health distribution footprint.

McKesson Corporation (US58155Q1031) stock is anchored by fiscal 2025 revenue of $359.9 billion and adjusted earnings growth of 31.3%, two figures that show why the shares remain a large-cap health care distribution name. The company’s latest investor relations framework, published on McKesson Investor Relations, puts those results alongside a business model that still generates scale through pharmacy, medical-surgical, and distribution operations.

Revenue at $359.9 billion

McKesson reported fiscal 2025 revenue of $359.9 billion, up from the prior year as the company continued to benefit from its high-volume distribution base. That scale matters because even modest margin changes can have a large earnings effect when the top line is measured in hundreds of billions of dollars.

The same fiscal 2025 reporting cycle also showed adjusted EPS growth of 31.3%, a comparison that is more useful for investors than revenue alone. A higher earnings growth rate than sales growth usually points to better operating leverage, improved mix, or both.

Adjusted EPS rises 31.3%

McKesson’s fiscal 2025 adjusted EPS increase of 31.3% gives the clearest read-through for valuation. A company of this size does not need a dramatic revenue surprise to move the stock narrative; sustaining profit growth is enough to keep the market focused on execution quality.

The company also reported a business structure that spans pharmaceuticals, oncology, and medical-surgical distribution, which helps explain why results are spread across several operating lines rather than one single product cycle. That diversification reduces dependence on any one franchise while keeping the revenue base broad.

Distribution scale still matters

For a distributor such as McKesson, the market usually watches volume, margins, and capital returns together rather than one isolated metric. Fiscal 2025 revenue of $359.9 billion and adjusted EPS growth of 31.3% together point to a company that kept scale intact while converting more of that scale into profit.

The relevance for investors is straightforward: when revenue is already this large, future share-price upside depends less on headline growth and more on whether the company can extend margin and earnings progression. That is why the earnings line matters more than the revenue line in the current setup.

Pharmacy and health care reach

McKesson’s product and service mix includes pharmaceutical distribution, oncology, and medical-surgical supply, giving it a footprint across large parts of the U.S. health care system. The business model is not built around one consumer product, but around recurring infrastructure that serves providers, pharmacies, and health care channels.

That breadth helps explain why the company remains relevant even in a period when investors often prefer faster-growing health care names. McKesson’s appeal is different: it is a scale-and-execution story, and fiscal 2025 showed both scale and earnings growth.

Market value and listing

McKesson trades on the NYSE under the symbol NYSE: MCK. With fiscal 2025 revenue at $359.9 billion and adjusted EPS growth at 31.3%, the stock’s valuation discussion continues to rest on profit conversion and capital discipline rather than pure sales momentum.

As a large-cap health care distribution company, McKesson remains one of the sector’s most closely watched earnings compounding stories, especially when the company can turn a $359.9 billion revenue base into double-digit earnings expansion.

McKesson stock facts

• Company: McKesson Corporation
• ISIN: US58155Q1031
• Ticker: NYSE: MCK
• Trading venue: NYSE
• Sector / Industry: Health Care / Health Care Distributors
• Index membership: S&P 500